{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Tian C"],"funding":["the National Science Foundation for Young Scientists of China 81702994 (AC), National Natural Science Foundation of China 81972454 and 82172801 (SY)"],"pagination":["2892"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8911181"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["23(5)"],"pubmed_abstract":["In recent years, three PARP inhibitors and three CDK4/6 inhibitors have been approved by the FDA for the treatment of recurrent ovarian cancer and advanced ER-positive breast cancer, respectively. However, the clinical benefits of the PARPi or CDK4/6i monotherapy are not as satisfied as expected and benefit only a fraction of patients. Current studies have shown therapeutic synergy for combinations of PARPi and CDK4/6i in breast and ovarian cancers with homologous recombination (HR) proficiency, which represents a new synthetic lethal strategy for treatment of these cancers regardless HR status. Thus, any compounds or strategies that can combine PARP and CDK4/6 inhibition will likely have great potential in improving clinic outcomes and in benefiting more patients. In this study, we develo"],"journal":["International journal of molecular sciences"],"pubmed_title":["A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer."],"pmcid":["PMC8911181"],"funding_grant_id":["81702994 (AC)，81972454 and 82172801 (SY)"],"pubmed_authors":["Xiang R","Li J","Fan Y","Lv X","Tian C","Lin Y","Wei Y","Wang Q","Sun P","Huang Z","Chang A","Chen Y","Yang S"],"additional_accession":[]},"is_claimable":false,"name":"A Novel CDK4/6 and PARP Dual Inhibitor ZC-22 Effectively Suppresses Tumor Growth and Improves the Response to Cisplatin Treatment in Breast and Ovarian Cancer.","description":"In recent years, three PARP inhibitors and three CDK4/6 inhibitors have been approved by the FDA for the treatment of recurrent ovarian cancer and advanced ER-positive breast cancer, respectively. However, the clinical benefits of the PARPi or CDK4/6i monotherapy are not as satisfied as expected and benefit only a fraction of patients. Current studies have shown therapeutic synergy for combinations of PARPi and CDK4/6i in breast and ovarian cancers with homologous recombination (HR) proficiency, which represents a new synthetic lethal strategy for treatment of these cancers regardless HR status. Thus, any compounds or strategies that can combine PARP and CDK4/6 inhibition will likely have great potential in improving clinic outcomes and in benefiting more patients. In this study, we develo","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2025-08-23T03:04:47.121Z","creation":"2025-08-21T09:50:22.957Z"},"accession":"S-EPMC8911181","cross_references":{"pubmed":["35270034"],"doi":["10.3390/ijms23052892"]}}